GV20-0251
- Generic Name
- GV20-0251
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)Squamous Head and Neck CarcinomapMMR/MSS Adenocarcinoma of the Colon or RectumCutaneous MelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- GV20 Therapeutics
- Target Recruit Count
- 268
- Registration Number
- NCT05669430
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath